BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

(Reuters) - Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...

The surging popularity of weight-loss drugs, expected to be a $150 billion market by early 2030s, has whetted investor appetite in companies looking to tap into the boom. BioAge priced its offering of ...

The health news update discusses Washington state's abortion pill stockpile as a safeguard, BioAge's successful IPO, a ...